{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T08:29:02Z","timestamp":1790152142956,"version":"4.0.1"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"21","license":[{"start":{"date-parts":[[2004,9,9]],"date-time":"2004-09-09T00:00:00Z","timestamp":1094688000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2004,9,9]],"date-time":"2004-09-09T00:00:00Z","timestamp":1094688000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Gene Ther"],"published-print":{"date-parts":[[2004,11,1]]},"DOI":"10.1038\/sj.gt.3302314","type":"journal-article","created":{"date-parts":[[2004,9,9]],"date-time":"2004-09-09T08:39:04Z","timestamp":1094719144000},"page":"1590-1598","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":37,"title":["Improved efficacy of gene therapy approaches for Pompe disease using a new, immune-deficient GSD-II mouse model"],"prefix":"10.1038","volume":"11","author":[{"given":"F","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"SX","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F","family":"Migone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Schneider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D","family":"Serra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"YT","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Amalfitano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2004,9,9]]},"reference":[{"key":"BF3302314_CR1","doi-asserted-by":"publisher","first-page":"145","DOI":"10.2174\/1566524024605789","volume":"2","author":"N Raben","year":"2002","unstructured":"Raben N, Plotz P, Byrne BJ . Acid alpha-glucosidase deficiency (glycogenosis type II, Pompe disease). Curr Mol Med 2002; 2: 145\u2013166.","journal-title":"Curr Mol Med"},{"key":"BF3302314_CR2","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1016\/S0021-9258(18)53985-5","volume":"268","author":"HA Wisselaar","year":"1993","unstructured":"Wisselaar HA et al. Structural functional changes of lysosomal acid alpha-glucosidase during intracellular transport maturation. J Biol Chem 1993; 268: 2223\u20132231.","journal-title":"J Biol Chem"},{"key":"BF3302314_CR3","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1042\/bj2720493","volume":"272","author":"LH Hoefsloot","year":"1990","unstructured":"Hoefsloot LH, Hoogeveen-Westerveld M, Reuser AJ, Oostra BA . Characterization of the human lysosomal alpha-glucosidase gene. Biochem J 1990; 272: 493\u2013497.","journal-title":"Biochem J"},{"key":"BF3302314_CR4","doi-asserted-by":"publisher","first-page":"S61","DOI":"10.1002\/mus.880181414","volume":"3","author":"AJ Reuser","year":"1995","unstructured":"Reuser AJ et al. Glycogenosis type II (acid maltase deficiency). Muscle Nerve 1995; 3: S61\u2013S69.","journal-title":"Muscle Nerve"},{"key":"BF3302314_CR5","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/S1357-4310(00)01694-4","volume":"6","author":"YT Chen","year":"2000","unstructured":"Chen YT, Amalfitano A . Towards a molecular therapy for glycogen storage disease type II (Pompe disease). Mol Med Today 2000; 6: 245\u2013251.","journal-title":"Mol Med Today"},{"key":"BF3302314_CR6","doi-asserted-by":"publisher","first-page":"2145","DOI":"10.1093\/hmg\/8.12.2145","volume":"8","author":"AG Bijvoet","year":"1999","unstructured":"Bijvoet AG et al. Human acid alpha-glucosidase from rabbit milk has therapeutic effect in mice with glycogen storage disease type II. Hum Mol Genet 1999; 8: 2145\u20132153.","journal-title":"Hum Mol Genet"},{"key":"BF3302314_CR7","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/S0140-6736(00)02533-2","volume":"356","author":"H Van den Hout","year":"2000","unstructured":"Van den Hout H et al. Recombinant human alpha-glucosidase from rabbit milk in Pompe patients. Lancet 2000; 356: 397\u2013398.","journal-title":"Lancet"},{"key":"BF3302314_CR8","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1073\/pnas.93.1.65","volume":"93","author":"JL Van Hove","year":"1996","unstructured":"Van Hove JL et al. High-level production of recombinant human lysosomal acid alpha-glucosidase in Chinese hamster ovary cells which targets to heart muscle corrects glycogen accumulation in fibroblasts from patients with Pompe disease. Proc Natl Acad Sci USA 1996; 93: 65\u201370.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BF3302314_CR9","doi-asserted-by":"publisher","first-page":"8861","DOI":"10.1073\/pnas.96.16.8861","volume":"96","author":"A Amalfitano","year":"1999","unstructured":"Amalfitano A et al. Systemic correction of the muscle disorder glycogen storage disease type II after hepatic targeting of a modified adenovirus vector encoding human acid-alpha-glucosidase. Proc Natl Acad Sci USA 1999; 96: 8861\u20138866.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BF3302314_CR10","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1089\/104303401750195917","volume":"12","author":"EY Ding","year":"2001","unstructured":"Ding EY et al. Long-term efficacy after [E1-, polymerase-] adenovirus-mediated transfer of human acid-alpha-glucosidase gene into glycogen storage disease type II knockout mice. Hum Gene Ther 2001; 12: 955\u2013965.","journal-title":"Hum Gene Ther"},{"key":"BF3302314_CR11","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1006\/mthe.2002.0563","volume":"5","author":"E Ding","year":"2002","unstructured":"Ding E et al. Efficacy of gene therapy for a prototypical lysosomal storage disease (GSD-II) is critically dependent on vector dose, transgene promoter, and the tissues targeted for vector transduction. Mol Ther 2002; 5: 436\u2013446.","journal-title":"Mol Ther"},{"key":"BF3302314_CR12","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1089\/104303401300042447","volume":"12","author":"DF Pauly","year":"2001","unstructured":"Pauly DF et al. Intercellular transfer of the virally derived precursor form of acid alpha-glucosidase corrects the enzyme deficiency in inherited cardioskeletal myopathy Pompe disease. Hum Gene Ther 2001; 12: 527\u2013538.","journal-title":"Hum Gene Ther"},{"key":"BF3302314_CR13","doi-asserted-by":"publisher","first-page":"2039","DOI":"10.1093\/hmg\/10.19.2039","volume":"10","author":"N Raben","year":"2001","unstructured":"Raben N et al. Conditional tissue-specific expression of the acid alpha-glucosidase (GAA) gene in the GAA knockout mice: implications for therapy. Hum Mol Genet 2001; 10: 2039\u20132047.","journal-title":"Hum Mol Genet"},{"key":"BF3302314_CR14","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1002\/jgm.355","volume":"5","author":"AJ McVie-Wylie","year":"2003","unstructured":"McVie-Wylie AJ et al. Multiple muscles in the AMD quail can be cross-corrected of pathologic glycogen accumulation after intravenous injection of an [E1-, polymerase-] adenovirus vector encoding human acid-alpha-glucosidase. J Gene Med 2003; 5: 399\u2013406.","journal-title":"J Gene Med"},{"key":"BF3302314_CR15","first-page":"132","volume":"3","author":"A Amalfitano","year":"2001","unstructured":"Amalfitano A et al. Recombinant human acid alpha-glucosidase enzyme therapy for infantile glycogen storage disease type II: results of a phase I\/II clinical trial. Genet Med 2001; 3: 132\u2013138.","journal-title":"Genet Med"},{"key":"BF3302314_CR16","doi-asserted-by":"publisher","first-page":"19086","DOI":"10.1074\/jbc.273.30.19086","volume":"273","author":"N Raben","year":"1998","unstructured":"Raben N et al. Targeted disruption of the acid alpha-glucosidase gene in mice causes an illness with critical features of both infantile and adult human glycogen storage disease type II. J Biol Chem 1998; 273: 19086\u201319092.","journal-title":"J Biol Chem"},{"key":"BF3302314_CR17","doi-asserted-by":"publisher","first-page":"10285","DOI":"10.1073\/pnas.93.19.10285","volume":"93","author":"T Blunt","year":"1996","unstructured":"Blunt T et al. Identification of a nonsense mutation in the carboxyl-terminal region of DNA-dependent protein kinase catalytic subunit in the SCID mouse. Proc Natl Acad Sci USA 1996; 93: 10285\u201310290.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BF3302314_CR18","doi-asserted-by":"publisher","first-page":"2438","DOI":"10.1073\/pnas.94.6.2438","volume":"94","author":"R Araki","year":"1997","unstructured":"Araki R et al. Nonsense mutation at Tyr-4046 in the DNA-dependent protein kinase catalytic subunit of severe combined immune deficiency mice. Proc Natl Acad Sci USA 1997; 94: 2438\u20132443.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BF3302314_CR19","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1073\/pnas.97.3.1002","volume":"97","author":"V Sandig","year":"2000","unstructured":"Sandig V et al. Optimization of the helper-dependent adenovirus system for production and potency in vivo. Proc Natl Acad Sci USA 2000; 97: 1002\u20131007.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BF3302314_CR20","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1172\/JCI1722","volume":"101","author":"T Kikuchi","year":"1998","unstructured":"Kikuchi T et al. Clinical and metabolic correction of pompe disease by enzyme therapy in acid maltase-deficient quail. J Clin Invest 1998; 101: 827\u2013833.","journal-title":"J Clin Invest"},{"key":"BF3302314_CR21","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1006\/mthe.2002.0580","volume":"5","author":"TJJ Fraites","year":"2002","unstructured":"Fraites TJJ et al. Correction of the enzymatic and functional deficits in a model of Pompe disease using adeno-associated virus vectors. Mol Ther 2002; 5: 571\u2013578.","journal-title":"Mol Ther"},{"key":"BF3302314_CR22","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1093\/hmg\/11.14.1637","volume":"11","author":"E Martin-Touaux","year":"2002","unstructured":"Martin-Touaux E et al. Muscle as a putative producer of acid alpha-glucosidase for glycogenosis type II gene therapy. Hum Mol Genet 2002; 11: 1637\u20131645.","journal-title":"Hum Mol Genet"},{"key":"BF3302314_CR23","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/S1525-0016(02)00055-2","volume":"7","author":"B Sun","year":"2003","unstructured":"Sun B et al. Long-term correction of glycogen storage disease type II with a hybrid Ad-AAV vector. Mol Ther 2003; 7: 193\u2013201.","journal-title":"Mol Ther"},{"key":"BF3302314_CR24","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1128\/JVI.72.1.180-190.1998","volume":"72","author":"P Loser","year":"1998","unstructured":"Loser P, Jennings GS, Strauss M, Sandig V . Reactivation of the previously silenced cytomegalovirus major immediate-early promoter in the mouse liver: involvement of NfkappaB. J Virol 1998; 72: 180\u2013190.","journal-title":"J Virol"},{"key":"BF3302314_CR25","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1016\/S1525-0016(02)90716-1","volume":"6","author":"N Raben","year":"2002","unstructured":"Raben N et al. Glycogen stored in skeletal but not in cardiac muscle in acid alpha-glucosidase mutant (Pompe) mice is highly resistant to transgene-encoded human enzyme. Mol Ther 2002; 6: 601\u2013608.","journal-title":"Mol Ther"},{"key":"BF3302314_CR26","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1203\/00006450-198807000-00021","volume":"24","author":"AT Van der Ploeg","year":"1988","unstructured":"Van der Ploeg AT et al. Receptor-mediated uptake of acid alpha-glucosidase corrects lysosomal glycogen storage in cultured skeletal muscle. Pediatr Res 1988; 24: 90\u201394.","journal-title":"Pediatr Res"},{"key":"BF3302314_CR27","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/S0925-4439(02)00229-6","volume":"1637","author":"RP Hesselink","year":"2003","unstructured":"Hesselink RP, Wagenmakers AJ, Drost MR, Van der Vusse GJ . Lysosomal dysfunction in muscle with special reference to glycogen storage disease type II. Biochim Biophys Acta 2003; 1637: 164\u2013170.","journal-title":"Biochim Biophys Acta"},{"key":"BF3302314_CR28","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1172\/JCI115025","volume":"87","author":"AT Van der Ploeg","year":"1991","unstructured":"Van der Ploeg AT et al. Intravenous administration of phosphorylated acid alpha-glucosidase leads to uptake of enzyme in heart skeletal muscle of mice. J Clin Invest 1991; 87: 513\u2013518.","journal-title":"J Clin Invest"},{"key":"BF3302314_CR29","first-page":"73","volume":"47","author":"F Martiniuk","year":"1990","unstructured":"Martiniuk F et al. Extensive genetic heterogeneity in patients with acid alpha glucosidase deficiency as detected by abnormalities of DNA and mRNA. Am J Hum Genet 1990; 47: 73\u201378.","journal-title":"Am J Hum Genet"}],"container-title":["Gene Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/3302314.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/3302314","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/3302314.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,30]],"date-time":"2022-03-30T04:16:06Z","timestamp":1648613766000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/3302314"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,9,9]]},"references-count":29,"journal-issue":{"issue":"21","published-print":{"date-parts":[[2004,11,1]]}},"alternative-id":["BF3302314"],"URL":"https:\/\/doi.org\/10.1038\/sj.gt.3302314","relation":{},"ISSN":["0969-7128","1476-5462"],"issn-type":[{"value":"0969-7128","type":"print"},{"value":"1476-5462","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,9,9]]},"assertion":[{"value":"30 December 2003","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 April 2004","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 September 2004","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}